Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women

Authors Gangadhara S, Bertelli G

Published 2 April 2009 Volume 2009:5 Pages 291—300

DOI https://doi.org/10.2147/TCRM.S3856

Review by Single-blind

Peer reviewer comments 2


Sharath Gangadhara, Gianfilippo Bertelli

South West Wales Cancer Institute, Singleton Hospital, Swansea, UK

Abstract: For more than 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer. However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting. Data on anastrozole’s long-term efficacy and tolerability are therefore of interest in clinical practice and will be reviewed here, especially in the light of the 100-month analysis of the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.

Keywords: anastrozole, aromatase inhibitors, breast cancer, adjuvant therapy

 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]